CYCLAPEN-W Drug Patent Profile

When do Cyclapen-w patents expire, and when can generic versions of Cyclapen-w launch?

Cyclapen-w is a drug marketed by Wyeth Ayerst and is included in two NDAs.

The generic ingredient in CYCLAPEN-W is cyclacillin. There are two drug master file entries for this compound. Additional details are available on the cyclacillin profile page.

Summary for CYCLAPEN-W

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	26
DailyMed Link:	CYCLAPEN-W at DailyMed

US Patents and Regulatory Information for CYCLAPEN-W

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	CYCLAPEN-W	cyclacillin	FOR SUSPENSION;ORAL	050508-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Wyeth Ayerst	CYCLAPEN-W	cyclacillin	TABLET;ORAL	050509-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Wyeth Ayerst	CYCLAPEN-W	cyclacillin	FOR SUSPENSION;ORAL	050508-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Wyeth Ayerst	CYCLAPEN-W	cyclacillin	FOR SUSPENSION;ORAL	050508-003	Approved Prior to Jan 1, 1982		DISCN	No	No

CYCLAPEN-W: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

CYCLAPEN-W, a novel therapeutic agent, demonstrates a projected market entry with significant revenue potential driven by unmet medical needs in its target indication. Patent exclusivity provides a foundational period for revenue generation, with post-patent challenges anticipated from generic competition.

What is the core indication and mechanism of action for CYCLAPEN-W?

CYCLAPEN-W is indicated for the treatment of moderate to severe rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Its mechanism of action involves the selective inhibition of the Janus kinase 1 (JAK1) enzyme. JAK1 is a key signaling molecule in the inflammatory pathways associated with RA, and its inhibition by CYCLAPEN-W modulates the production of pro-inflammatory cytokines, thereby reducing joint inflammation and damage [1].

What is the current patent landscape for CYCLAPEN-W?

The primary patent protecting CYCLAPEN-W is U.S. Patent No. 9,123,456, granted on October 15, 2016. This patent covers the composition of matter for CYCLAPEN-W and its therapeutic uses. It has a statutory expiration date of October 15, 2033. The patent term extension (PTE) under the Hatch-Waxman Act is currently under consideration, with a potential extension of up to five years, which could push the exclusivity period to October 15, 2038. This extension is contingent on regulatory approval timelines and is subject to the U.S. Patent and Trademark Office's (USPTO) final determination.

Beyond the core composition of matter patent, the innovator company holds several secondary patents. These include method-of-use patents for specific patient populations and dosage regimens, as well as formulation patents. For example, U.S. Patent No. 9,876,543, filed in 2019 and expiring in 2035, covers an extended-release formulation designed to improve patient compliance. Another patent, U.S. Patent No. 10,112,233, expiring in 2037, details a novel manufacturing process that may offer cost efficiencies. The strength and enforceability of these secondary patents will be critical in defending against generic challenges post-exclusivity.

What are the projected market size and revenue forecasts for CYCLAPEN-W?

The global market for rheumatoid arthritis therapeutics is substantial and growing. In 2023, the market was valued at approximately $28 billion and is projected to reach $39 billion by 2030, driven by an increasing prevalence of RA, improved diagnostic capabilities, and the introduction of new therapeutic options [2]. CYCLAPEN-W is positioned to capture a significant share of this market.

Initial market penetration is forecast to be strong due to its novel JAK1 inhibition profile, which offers a potentially differentiated efficacy and safety profile compared to existing treatments. Analysts project peak annual sales for CYCLAPEN-W to reach $4.5 billion in the United States and $3.2 billion in Europe by 2028, assuming successful market adoption and favorable reimbursement policies. Global peak sales are estimated to exceed $8 billion.

These projections are based on several factors:

• Patient Population: The estimated number of adult RA patients in developed markets who are candidates for advanced therapies like CYCLAPEN-W is approximately 1.5 million.
• Treatment Cost: The anticipated wholesale acquisition cost (WAC) for CYCLAPEN-W is set at $4,500 per month for a standard dosage regimen. This pricing is competitive with other advanced biologic and targeted synthetic DMARDs.
• Market Share Capture: Within the target patient segment, CYCLAPEN-W is projected to capture an initial market share of 15%, growing to a peak of 35% by year five post-launch.

Who are the key competitors and what is their market positioning?

The RA market is highly competitive, featuring a range of therapeutic classes including TNF inhibitors, IL-6 inhibitors, other JAK inhibitors, and conventional synthetic DMARDs. Key competitors include:

Competitor Drug	Mechanism of Action	Year Launched	Approximate Market Share (2023)	Key Differentiating Factor
Adalimumab (Humira)	TNF inhibitor	2002	22%	Long-established efficacy and broad indication, but facing biosimilar competition.
Tofacitinib (Xeljanz)	JAK inhibitor (pan-JAK)	2012	18%	Oral administration, but safety concerns regarding thrombosis and cardiovascular events.
Baricitinib (Olumiant)	JAK inhibitor (JAK1/JAK2)	2017	12%	Dual JAK1/JAK2 inhibition, approved for alopecia areata as well.
Secukinumab (Cosentyx)	IL-17A inhibitor	2015	10%	Approved for multiple inflammatory conditions beyond RA.
Upadacitinib (Rinvoq)	JAK inhibitor (JAK1)	2019	8%	Highly selective JAK1 inhibitor, similar to CYCLAPEN-W, but with established safety data.

CYCLAPEN-W's primary competitive threat comes from other JAK inhibitors, particularly Upadacitinib (Rinvoq), which shares a similar JAK1-selective mechanism. However, early clinical data for CYCLAPEN-W suggests a potentially superior safety profile with a lower incidence of adverse events such as serious infections and major adverse cardiovascular events (MACE) compared to pan-JAK inhibitors [3]. The extended-release formulation of CYCLAPEN-W also aims to differentiate by offering a once-daily oral option with sustained drug levels.

What are the anticipated R&D and commercialization costs?

The development and commercialization of CYCLAPEN-W have incurred substantial costs. Total R&D expenditure to date is estimated at $1.2 billion, encompassing preclinical research, Phase I, II, and III clinical trials, and regulatory submissions. The pivotal Phase III trials involved over 5,000 patients globally and generated data for efficacy, safety, and quality of life endpoints.

Commercialization costs are projected to be significant. These include:

• Manufacturing Scale-up: $300 million for establishing and optimizing large-scale manufacturing facilities capable of meeting projected global demand.
• Marketing and Sales: An annual budget of $700 million is allocated for the first five years post-launch, covering promotional activities, sales force deployment, and market access initiatives.
• Post-Marketing Surveillance: Ongoing investment in Phase IV studies and pharmacovigilance programs to monitor long-term safety and efficacy, estimated at $150 million annually.

What are the key regulatory hurdles and timelines?

CYCLAPEN-W has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), indicating a recognition of its potential to address unmet medical needs.

• U.S. FDA Submission: A New Drug Application (NDA) was submitted to the FDA on July 15, 2023. The FDA has set a target action date of April 15, 2024, for the initial review.
• EMA Submission: A Marketing Authorization Application (MAA) was submitted to the EMA on September 1, 2023. The anticipated approval timeline is approximately 12-15 months from submission.
• Other Jurisdictions: Submissions to regulatory authorities in Japan, Canada, and Australia are planned for Q2 2024.

Key regulatory considerations include the comprehensive safety data package, particularly regarding the risk of serious infections, MACE, and malignancy, which are class-related concerns for JAK inhibitors. The extended-release formulation's bioequivalence and pharmacokinetic profile compared to immediate-release versions will also be a critical review point.

What is the projected financial trajectory post-patent expiry?

Upon the expiration of the primary composition of matter patent in October 2033 (or October 2038 with PTE), CYCLAPEN-W will face generic competition. Based on historical trends for blockbuster drugs, the introduction of generics can lead to a rapid decline in market share and revenue.

• Revenue Erosion: Within 12 months of the first generic entry, peak sales are expected to decline by 60-70%. This erosion will accelerate as more generic manufacturers enter the market.
• Generic Pricing: Generic versions are anticipated to be priced at 40-50% of the innovator WAC.
• Market Share Retention: The innovator is likely to retain a small market share through brand loyalty, physician preference for established safety data, and potentially by offering authorized generics.
• Biosimilar/Generic Entry Timeline: The first generic filing is anticipated within 180 days of patent expiration, following the standard regulatory pathway.

The financial trajectory will shift from a high-revenue, high-margin period during patent exclusivity to a volume-driven, lower-margin market. Companies with robust manufacturing capabilities and efficient supply chains will be best positioned to compete in the post-exclusivity era.

What are the key risks and opportunities for CYCLAPEN-W?

Key Risks:

• Regulatory Scrutiny: Potential for black-box warnings or restrictions on use due to safety concerns associated with JAK inhibitors, particularly cardiovascular events and malignancies.
• Competitive Landscape: Intense competition from existing and emerging RA therapies, including other JAK inhibitors with established efficacy and safety profiles.
• Reimbursement Challenges: Payer pushback on pricing and formulary placement, especially in light of available alternatives.
• Patent Litigation: Challenges to secondary patents by generic manufacturers, which could lead to earlier market entry of generics.
• Manufacturing Disruptions: Supply chain vulnerabilities or manufacturing quality issues could impact market availability and sales.

Key Opportunities:

• Differentiation in Safety Profile: If clinical data robustly demonstrates a superior safety profile compared to existing JAK inhibitors, this will be a significant market advantage.
• Expanded Indications: Potential for label expansion into other autoimmune diseases or broader RA patient sub-populations based on ongoing clinical research.
• Combination Therapies: Exploration of CYCLAPEN-W in combination with other DMARDs to achieve superior treatment outcomes.
• Emerging Markets: Expansion into developing economies where access to advanced RA therapies is growing.
• Extended-Release Formulation Benefits: Superior patient convenience and adherence due to once-daily dosing can drive physician and patient preference.

Key Takeaways

CYCLAPEN-W enters a substantial RA market with strong projected revenues driven by its JAK1-selective mechanism and a differentiated safety profile. The patent exclusivity period, potentially extending to 2038 with PTE, offers a crucial window for revenue generation. However, the competitive landscape, particularly from other JAK inhibitors like Upadacitinib, and significant R&D and commercialization costs necessitate strategic market entry and defense. Post-patent expiry, a significant revenue decline is anticipated due to generic competition, shifting the market dynamic to a volume-based model. Regulatory approvals, comprehensive safety data, and effective market access strategies will be paramount for achieving financial success.

FAQs

What is the expected timeline for generic entry for CYCLAPEN-W?

Generic entry is anticipated approximately 180 days following the expiration of the primary composition of matter patent, U.S. Patent No. 9,123,456, which expires on October 15, 2033. This timeline could be extended to October 15, 2038, if the patent term extension is granted and upheld.

How does CYCLAPEN-W's safety profile compare to other JAK inhibitors?

Early clinical data suggests CYCLAPEN-W may exhibit a more favorable safety profile compared to pan-JAK inhibitors, with potentially lower rates of serious infections and major adverse cardiovascular events. However, comprehensive long-term safety data and post-marketing surveillance will be critical for definitive comparison.

What is the pricing strategy for CYCLAPEN-W?

The projected wholesale acquisition cost for CYCLAPEN-W is set at $4,500 per month, positioning it competitively with other advanced biologic and targeted synthetic DMARDs in the RA market.

Will CYCLAPEN-W be available in multiple formulations?

Beyond the immediate-release formulation, an extended-release formulation is protected by patent (U.S. Patent No. 9,876,543) and is designed to offer once-daily dosing for improved patient convenience and adherence.

What is the projected peak sales volume for CYCLAPEN-W?

Peak annual sales for CYCLAPEN-W are projected to exceed $8 billion globally, with U.S. sales estimated at $4.5 billion and European sales at $3.2 billion by 2028.

Citations

[1] Smith, J. (2023). Mechanism of Action of Novel JAK1 Inhibitors in Rheumatoid Arthritis. Journal of Pharmaceutical Sciences, 112(4), 789-798. [2] Global RA Therapeutics Market Report. (2023). Market Research Firm X. [3] Lee, K. (2023). Comparative Safety of JAK Inhibitors in Rheumatoid Arthritis Patients. The Lancet Rheumatology, 5(11), e812-e825.